Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-668-5 | CAS number: 999-97-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In a 90-day repeated dose toxicity study conducted according to OECD Test Guidelines 413 and in compliance with GLP, nose-only inhalation exposure of 1,1,1,3,3,3-hexamethyldisilazane (CAS 999-97-3, EC 213-668-5) at concentrations of 25, 75 or 400 ppm to Sprague-Dawley rats for 6 hours per day, 5 days per week for 13 weeks resulted in minor and reversible changes at the highest concentration. Renal effects in male rats were observed at all concentrations, but these findings were consistent with alpha-2u-nephropathy and therefore of no toxicological significance to humans. Based on the results in this study, the NOAEC was considered to be higher than or equal to 400 ppm (equivalent to 2640 mg/m3), the highest concentration tested (Harlan 2014).
1,1,1,3,3,3-Hexamethyldisilazane is rapidly hydrolysed in contact with moisture releasing trimethylsilanol and ammonia.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17 April to 27 August 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study was conducted in accordance with an appropriate guideline and in compliance with GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- yes
- Remarks:
- (relative humidity of chamber atmosphere)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.29 (Sub-Chronic Inhalation Toxicity:90-Day Study)
- Deviations:
- yes
- Remarks:
- (relative humidity of chamber atmosphere)
- Principles of method if other than guideline:
- For technical reasons, the relative humidity value of the chamber atmosphere was below the range given by the guidelines. The reason is the dried, pressurized air used for vapor generation, in combination with heating the test item in the nebulizer to 68 - 76 °C. This deviation from the guidelines has no influence on the results of the study, based on the absence of any findings in the respiratory tract and the circumstance that dry air generally worsens any findings in the respiratory tract due to loss of the protective mucus layer on the lining epithelium.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD(SD)IGS
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Germany
- Age at study initiation: 8 weeks
- Weight at study initiation: 268-297g (males); 163-200g (females)
- Fasting period before study: no
- Housing: Makrolon type-4 cages with wire mesh tops and sterilized standard softwood bedding (Lignocel), including paper enrichment (Enviro-dri)
- Diet (ad libitum): Pelleted standard Harlan Teklad 2914C rodent maintenance diet (Provimi Kliba AG, Switzerland),
- Water (ad libitum): community tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/- 3
- Humidity (%): 30-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: To: 17 April to 27 August 2013 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: nose-only, flow-past exposure chamber
- Method of holding animals in test chamber: restraint tubes
- Source and rate of air:
- Method of conditioning air:
- System of generating vapour: 1,1,1,3,3,3-Hexamethyldisilazane was pumped into a glass flask. Compressed, filtered, and dried air was supplied into the glass flask through a metal nebulization tube. The glass flask was kept between a temperature of 68 and 76 °C with a thermal regulating device set to facilitate the process of vaporization.
- Temperature, humidity, pressure in air chamber: 19.9 to 22.6 degrees C: 0.0 to 4.0% ; slight positive pressure to outside
- Air flow rate: 0.75-1.0L/min
- Air change rate:
- Method of particle size determination:
- Treatment of exhaust air:
TEST ATMOSPHERE
- Brief description of analytical method used: nominal - wieighing of test susbtance; chemical - on-line GC
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of 1,1,1,3,3,3-Hexamethyldisilazane was measured at least once per hour of exposure per on-line GC for groups 1 to 4.
Analytical concentrations were determined by GC. The method of analysis was performed according to the conditions listed below.
- Column: HP-5MS (30 m, 0.25 mm, 0.25 μm)
- Injector: 250 °C
- Oven: 40 °C for 1 min, then 40 °C/min to 100 °C for 0 min, then 50 °C/min to 230 °C for 1 min
- Detector: 280 °C
- Calibration:
A calibration curve consisting of at least 6 points and ranging between concentrations of approximately 10 ppm to approximately 500 ppm were constructed from the test item in gas bags as part of the technical trials. The calibration gas bags were prepared at each concentration and at least two independent gas bags were used.
- Acceptance Criteria:
The coefficients of variation were below 3.1% (acceptance criteria of >10%) for all calibration gas bag samples at each concentration. The correlation coefficient of the used regression was >0.9989 (acceptance criteria of >0.985). Accordingly, the acceptance criteria were met.
Daily standards constructed from the test item in gas bags were sampled at one of the chamber-lines and used to check the integrity of the sampling line and check the GC calibration. Plots of the peak height used for the calibration were used to assess trends regarding system stability. The acceptance criterion for standard samples was an accuracy of 90 - 110% of the theoretical value. The acceptance criteria for standard samples were met for each exposure session.
The test item was used as the analytical standard. - Duration of treatment / exposure:
- 6 hours
- Frequency of treatment:
- 5 days/week for 13 weeks, followed by 4 week recovery period for sub-group of Control and high dose
- Dose / conc.:
- 0 ppm (nominal)
- Remarks:
- Group 1 - Control Group
- Dose / conc.:
- 25 ppm (nominal)
- Remarks:
- Group 2 (165 mg/m3)
- Dose / conc.:
- 75 ppm (nominal)
- Remarks:
- Group 3 (495 mg/m3)
- Dose / conc.:
- 400 ppm (nominal)
- Remarks:
- Group 4 (2640 mg/m3)
- No. of animals per sex per dose:
- 20 Control and high dose, 10 low and intermediate dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: dose concentrations based on previous OECD 422 inhalation study
- Post-exposure recovery period in satellite groups: 4 weeks - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily during dosing period, once daily during recovery period
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily during dosing period, once weekly during recovery period
BODY WEIGHT: Yes
- Time schedule for examinations: twice weekly during dosing period, once weekly during recovery period
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes
- Time schedule for examinations: weekly
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: before dosing started and Week 13
- Dose groups that were examined: all (not recovery animals in Week 13)
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to necropsy at end of dosing or recovery period
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes
- How many animals: 10 sex/group
- Parameters checked in table No. 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to necropsy at end of dosing or recovery period
- Animals fasted: Yes
- How many animals: 10 sex/group
- Parameters checked in table No. 2 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: 18 hour period prior to necropsy at end of dosing or recovery period
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked in table No. 3 were examined.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
HISTOPATHOLOGY: Yes (see table) - Statistics:
- The following statistical methods were used to analyze the food consumption, body weight, ophthalmoscopic examinations, macroscopic findings, organ weights and ratios, as well as clini¬cal laboratory data:
• The two-sided Dunnett-test (many to one t-test) based on a pooled variance estimate was applied if the variables could be assumed to follow a normal distribution for the comparison of the treated groups and the control groups for each sex.
• The Steel-test (many-one rank test) was applied instead of the Dunnett-test when the data could not be assumed to follow a normal distribution.
• The two-sided Fisher's exact-test was applied to the ophthalmo-scopic and macroscopic findings. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Ataxia and decreased activity were noted in all animals in the high dose from treatment start onwards. Ataxia was recorded until weeks 8 and 11 in males and females, respectively, and decreased activity was recorded until week 3 for both sexes. Based on adaptation the animals showed during the treatment and on the complete reversibility of the findings during recovery, these findings are considered to be non-adverse.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no unscheduled deaths during the course of the study.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Lower body weight gain for high dose animals in both sexes during treatment period. An increased body weight gain was recorded in males during the recovery period.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Lower for high dose males during treatment period and for high dose females during first two weeks of treatment period. An increased food intake was noted during recovery.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No ophthalmoscopic findings were observed which were considered to be attributable to exposure with the test item
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Total red blood cells and hematocrit were slightly but statistically significantly higher at the end of the treatment period in females at 400 ppm. These findings had completely reversed at the end of the recovery period.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Sodium, potassium and chloride levels were higher at the end of the treatment period in females at 400 ppm. In addition, total protein was lower for those animals. These findings had completely reversed at the end of the recovery period.
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The pH value was lower at the end of the treatment period in males at 400 ppm. This finding had completely reversed at the end of the recovery period.
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Absolute and relative liver weights were higher in females at 400 ppm. In the absence of any histopathological findings in the livers and based on the reversibility
that was observed during the recovery period, this finding is considered to be adaptive. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In comparison to controls the incidence and severity of increased intra-epithelial hyaline droplets and focal or multifocal basophilic tubules was greater in all the male treated groups. In addition in 2/10 males given 400 ppm granular casts were present at the cortico-medullary junction of the kidneys. These findings were all considered to be consistent with a diagnosis of alpha-2µ-nephropathy and therefore of no toxicological significance to humans.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not specified
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- >= 400 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other:
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 400 ppm (nominal)
- System:
- urinary
- Organ:
- kidney
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- no
- Conclusions:
- In a repeated dose toxicity study conducted according to OECD Test Guidelines 413 and in compliance with GLP, nose-only inhalation exposure of 1,1,1,3,3,3-hexamethyldisilazane (CAS 999-97-3, EC 213-668-5) at concentrations of 25, 75 or 400 ppm to Sprague-Dawley rats for 6 hours per day, 5 days per week for 13 weeks resulted in minor and reversible changes at the highest concentration. Renal effects in male rats were observed at all concentrations, but these findings were consistent with alpha-2u-nephropathy and therefore of no toxicological significance to humans. Based on the results in this study, the NOAEC was considered to be higher than or equal to 400 ppm, the highest concentration tested.
Reference
Table 1 - Exposure Conditions
Group |
Temperature [°C] |
Relative Humidity [%] |
Oxygen Concentration [%] |
1 |
22.4 ± 0.2 (n=66) |
0.0 ± 0.0 (n=66) |
20.2 ± 0.0 (n=66) |
2 |
22.2 ± 0.1 (n=66) |
3.0 ± 0.1 (n=66) |
20.2 ± 0.0 (n=66) |
3 |
22.1 ± 0.2 (n=66) |
3.0 ± 0.5 (n=66) |
20.0 ± 0.0 (n=66) |
4 |
22.2 ± 0.1 (n=66) |
3.9 ± 0.1 (n=66) |
20.2 ± 0.1 (n=66) |
For technical reasons, the relative humidity value of the chamber atmosphere was below the range given by the guidelines. The reason is the dried, pressurized air used for vapor generation, in combination with heating the test item in the nebulizer to 68 – 76 °C. This deviation from the guidelines has no influence on the results of the study, based on the absence of any findings in the respiratory tract and the circumstance that dry air generally worsens any findings in the respiratory tract due to loss of the protective mucus layer on the lining epithelium.
Table 2 - Test Atmosphere Concentrations
Group |
Chemically Determined AtmosphereConcentration [ppm] |
TargetAtmosphereConcentration [ppm] |
Atmosphere ConcentrationsRelative to Target |
2 |
25.0 ± 0.5 (n=66, CV=1.8%) |
25 |
100.0% |
3 |
75.0 ± 1.6 (n=66, CV=2.2%) |
75 |
100.0% |
4 |
400 ± 4 (n=66, CV=1.1%) |
400 |
100.0% |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEC
- 2 640 mg/m³
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17 April to 27 August 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study was conducted in accordance with an appropriate guideline and in compliance with GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- yes
- Remarks:
- (relative humidity of chamber atmosphere)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.29 (Sub-Chronic Inhalation Toxicity:90-Day Study)
- Deviations:
- yes
- Remarks:
- (relative humidity of chamber atmosphere)
- Principles of method if other than guideline:
- For technical reasons, the relative humidity value of the chamber atmosphere was below the range given by the guidelines. The reason is the dried, pressurized air used for vapor generation, in combination with heating the test item in the nebulizer to 68 - 76 °C. This deviation from the guidelines has no influence on the results of the study, based on the absence of any findings in the respiratory tract and the circumstance that dry air generally worsens any findings in the respiratory tract due to loss of the protective mucus layer on the lining epithelium.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD(SD)IGS
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Germany
- Age at study initiation: 8 weeks
- Weight at study initiation: 268-297g (males); 163-200g (females)
- Fasting period before study: no
- Housing: Makrolon type-4 cages with wire mesh tops and sterilized standard softwood bedding (Lignocel), including paper enrichment (Enviro-dri)
- Diet (ad libitum): Pelleted standard Harlan Teklad 2914C rodent maintenance diet (Provimi Kliba AG, Switzerland),
- Water (ad libitum): community tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/- 3
- Humidity (%): 30-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: To: 17 April to 27 August 2013 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: nose-only, flow-past exposure chamber
- Method of holding animals in test chamber: restraint tubes
- Source and rate of air:
- Method of conditioning air:
- System of generating vapour: 1,1,1,3,3,3-Hexamethyldisilazane was pumped into a glass flask. Compressed, filtered, and dried air was supplied into the glass flask through a metal nebulization tube. The glass flask was kept between a temperature of 68 and 76 °C with a thermal regulating device set to facilitate the process of vaporization.
- Temperature, humidity, pressure in air chamber: 19.9 to 22.6 degrees C: 0.0 to 4.0% ; slight positive pressure to outside
- Air flow rate: 0.75-1.0L/min
- Air change rate:
- Method of particle size determination:
- Treatment of exhaust air:
TEST ATMOSPHERE
- Brief description of analytical method used: nominal - wieighing of test susbtance; chemical - on-line GC
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of 1,1,1,3,3,3-Hexamethyldisilazane was measured at least once per hour of exposure per on-line GC for groups 1 to 4.
Analytical concentrations were determined by GC. The method of analysis was performed according to the conditions listed below.
- Column: HP-5MS (30 m, 0.25 mm, 0.25 μm)
- Injector: 250 °C
- Oven: 40 °C for 1 min, then 40 °C/min to 100 °C for 0 min, then 50 °C/min to 230 °C for 1 min
- Detector: 280 °C
- Calibration:
A calibration curve consisting of at least 6 points and ranging between concentrations of approximately 10 ppm to approximately 500 ppm were constructed from the test item in gas bags as part of the technical trials. The calibration gas bags were prepared at each concentration and at least two independent gas bags were used.
- Acceptance Criteria:
The coefficients of variation were below 3.1% (acceptance criteria of >10%) for all calibration gas bag samples at each concentration. The correlation coefficient of the used regression was >0.9989 (acceptance criteria of >0.985). Accordingly, the acceptance criteria were met.
Daily standards constructed from the test item in gas bags were sampled at one of the chamber-lines and used to check the integrity of the sampling line and check the GC calibration. Plots of the peak height used for the calibration were used to assess trends regarding system stability. The acceptance criterion for standard samples was an accuracy of 90 - 110% of the theoretical value. The acceptance criteria for standard samples were met for each exposure session.
The test item was used as the analytical standard. - Duration of treatment / exposure:
- 6 hours
- Frequency of treatment:
- 5 days/week for 13 weeks, followed by 4 week recovery period for sub-group of Control and high dose
- Dose / conc.:
- 0 ppm (nominal)
- Remarks:
- Group 1 - Control Group
- Dose / conc.:
- 25 ppm (nominal)
- Remarks:
- Group 2 (165 mg/m3)
- Dose / conc.:
- 75 ppm (nominal)
- Remarks:
- Group 3 (495 mg/m3)
- Dose / conc.:
- 400 ppm (nominal)
- Remarks:
- Group 4 (2640 mg/m3)
- No. of animals per sex per dose:
- 20 Control and high dose, 10 low and intermediate dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: dose concentrations based on previous OECD 422 inhalation study
- Post-exposure recovery period in satellite groups: 4 weeks - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily during dosing period, once daily during recovery period
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily during dosing period, once weekly during recovery period
BODY WEIGHT: Yes
- Time schedule for examinations: twice weekly during dosing period, once weekly during recovery period
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes
- Time schedule for examinations: weekly
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: before dosing started and Week 13
- Dose groups that were examined: all (not recovery animals in Week 13)
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to necropsy at end of dosing or recovery period
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes
- How many animals: 10 sex/group
- Parameters checked in table No. 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to necropsy at end of dosing or recovery period
- Animals fasted: Yes
- How many animals: 10 sex/group
- Parameters checked in table No. 2 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: 18 hour period prior to necropsy at end of dosing or recovery period
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked in table No. 3 were examined.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
HISTOPATHOLOGY: Yes (see table) - Statistics:
- The following statistical methods were used to analyze the food consumption, body weight, ophthalmoscopic examinations, macroscopic findings, organ weights and ratios, as well as clini¬cal laboratory data:
• The two-sided Dunnett-test (many to one t-test) based on a pooled variance estimate was applied if the variables could be assumed to follow a normal distribution for the comparison of the treated groups and the control groups for each sex.
• The Steel-test (many-one rank test) was applied instead of the Dunnett-test when the data could not be assumed to follow a normal distribution.
• The two-sided Fisher's exact-test was applied to the ophthalmo-scopic and macroscopic findings. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Ataxia and decreased activity were noted in all animals in the high dose from treatment start onwards. Ataxia was recorded until weeks 8 and 11 in males and females, respectively, and decreased activity was recorded until week 3 for both sexes. Based on adaptation the animals showed during the treatment and on the complete reversibility of the findings during recovery, these findings are considered to be non-adverse.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no unscheduled deaths during the course of the study.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Lower body weight gain for high dose animals in both sexes during treatment period. An increased body weight gain was recorded in males during the recovery period.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Lower for high dose males during treatment period and for high dose females during first two weeks of treatment period. An increased food intake was noted during recovery.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No ophthalmoscopic findings were observed which were considered to be attributable to exposure with the test item
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Total red blood cells and hematocrit were slightly but statistically significantly higher at the end of the treatment period in females at 400 ppm. These findings had completely reversed at the end of the recovery period.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Sodium, potassium and chloride levels were higher at the end of the treatment period in females at 400 ppm. In addition, total protein was lower for those animals. These findings had completely reversed at the end of the recovery period.
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The pH value was lower at the end of the treatment period in males at 400 ppm. This finding had completely reversed at the end of the recovery period.
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Absolute and relative liver weights were higher in females at 400 ppm. In the absence of any histopathological findings in the livers and based on the reversibility
that was observed during the recovery period, this finding is considered to be adaptive. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In comparison to controls the incidence and severity of increased intra-epithelial hyaline droplets and focal or multifocal basophilic tubules was greater in all the male treated groups. In addition in 2/10 males given 400 ppm granular casts were present at the cortico-medullary junction of the kidneys. These findings were all considered to be consistent with a diagnosis of alpha-2µ-nephropathy and therefore of no toxicological significance to humans.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not specified
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- >= 400 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other:
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 400 ppm (nominal)
- System:
- urinary
- Organ:
- kidney
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- no
- Conclusions:
- In a repeated dose toxicity study conducted according to OECD Test Guidelines 413 and in compliance with GLP, nose-only inhalation exposure of 1,1,1,3,3,3-hexamethyldisilazane (CAS 999-97-3, EC 213-668-5) at concentrations of 25, 75 or 400 ppm to Sprague-Dawley rats for 6 hours per day, 5 days per week for 13 weeks resulted in minor and reversible changes at the highest concentration. Renal effects in male rats were observed at all concentrations, but these findings were consistent with alpha-2u-nephropathy and therefore of no toxicological significance to humans. Based on the results in this study, the NOAEC was considered to be higher than or equal to 400 ppm, the highest concentration tested.
Reference
Table 1 - Exposure Conditions
Group |
Temperature [°C] |
Relative Humidity [%] |
Oxygen Concentration [%] |
1 |
22.4 ± 0.2 (n=66) |
0.0 ± 0.0 (n=66) |
20.2 ± 0.0 (n=66) |
2 |
22.2 ± 0.1 (n=66) |
3.0 ± 0.1 (n=66) |
20.2 ± 0.0 (n=66) |
3 |
22.1 ± 0.2 (n=66) |
3.0 ± 0.5 (n=66) |
20.0 ± 0.0 (n=66) |
4 |
22.2 ± 0.1 (n=66) |
3.9 ± 0.1 (n=66) |
20.2 ± 0.1 (n=66) |
For technical reasons, the relative humidity value of the chamber atmosphere was below the range given by the guidelines. The reason is the dried, pressurized air used for vapor generation, in combination with heating the test item in the nebulizer to 68 – 76 °C. This deviation from the guidelines has no influence on the results of the study, based on the absence of any findings in the respiratory tract and the circumstance that dry air generally worsens any findings in the respiratory tract due to loss of the protective mucus layer on the lining epithelium.
Table 2 - Test Atmosphere Concentrations
Group |
Chemically Determined AtmosphereConcentration [ppm] |
TargetAtmosphereConcentration [ppm] |
Atmosphere ConcentrationsRelative to Target |
2 |
25.0 ± 0.5 (n=66, CV=1.8%) |
25 |
100.0% |
3 |
75.0 ± 1.6 (n=66, CV=2.2%) |
75 |
100.0% |
4 |
400 ± 4 (n=66, CV=1.1%) |
400 |
100.0% |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEC
- 2 640 mg/m³
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In the key repeated dose toxicity study conducted according to OECD Test Guideline 413 and in compliance with GLP, Sprague-Dawley rats were exposed, nose-only, to 1,1,1,3,3,3-hexamethyldisilazane vapour (CAS 999-97-3, EC 213-668-5) for 6 hours a day, 5 days a week for 13 weeks, followed by a 4 -week recovery period, at 0, 25, 75 or 400 ppm.
Clinical signs of decreased activity and ataxia was recorded after dose administration but not the following day and was therefore considered not to be adverse.
Minor effects on body weight and food consumption recorded at 400 ppm at the end of the exposure period but not after the 4 -week recovery period were considered not to be adverse. The changes in some haematology, clinical chemistry and urinalysis parameters were slight and/or only noted in one sex and/or without pathological correlate and had completely reversed by the end of the recovery period so were considered not to be adverse. The increase in liver weight was in the absence of any histopathological changes in the liver and was reversible during the recovery period and so was considered to be adaptive and therefore not adverse. The renal changes, including increased incidence and severity of intra-epithelial hyaline droplets or multifocal basophilic tubules in males at all doses was considered to be consistent with alpha-2u-nephropathy and therefore of no toxicological relevance to humans (Swenberg, 1993). The NOAEC was therefore considered to be 400 ppm (equivalent to 2640 mg/m3), the highest concentration tested (Harlan, 2014).
In a dose range-finding study based on a protocol equivalent to OECD Test Guideline 412 with some deviations and no compliance with GLP, undiluted 1,1,1,3,3,3-hexamethyldisilazane was administered to Sprague-Dawley rats (5/sex/dose) as a vapour at target concentrations of 0, 30, 100 and 400 ppm for six hours/day on seven consecutive days. Body and feeder weights were recorded prior to the first exposure and on Day 8. Daily observations for clinical signs of toxicity, as well as mortality and morbidity were conducted. Each animal underwent a gross necropsy on Day 8. Post-exposure observations in the highest dose group (actual concentration 584 ppm) consisted of decreased to absent activity and severe uncoordinated gait, or the inability to walk. Decreased activity and slight uncoordinated gait were noted occasionally in a few of the mid dose group (actual concentration 307 ppm). In all cases the effects were transient and animals recovered before the next exposure. The gross necropsy revealed no abnormal findings. Mean body weights, on Day 8, in the 307 and 584 (statistically significant) ppm groups were reduced in a dose-dependent manner. Body weight gains in the 307 and 584 ppm groups were statistically significantly reduced in a dose-dependent manner, and in the highest dose group animals lost weight over the eight-day period. There was a statistically significant reduction in food consumption in 307 and 584 ppm females, and 584 ppm males. The NOAEC for 1,1,1,3,3,3-hexamethyldisilazane was concluded to be 107 ppm based on clinical observations and statistically significant and/or exposure-related differences observed for body weights, body weight gains and food consumption when compared to controls. The study has been used to provide a rational basis to select the exposure levels for the subsequent repeated dose inhalation toxicity with the reproduction/developmental toxicity study, which is described below (Dow Corning Corporation 2007).
In a supporting repeated dose inhalation toxicity with the reproduction/developmental toxicity screening test conducted according to OECD Test Guideline 422 and in compliance with GLP, Sprague-Dawley rats were exposed, whole body, to 1,1,1,3,3,3-hexamethyldisilazane vapour for 6 hours/day, 7 days/week for 4 weeks at 0, 25, 100 or 400 ppm. Each exposure group consisted of 10 male and 20 female rats. Females were further divided into a toxicity and reproductive group consisting of 10 animals each (the results of the reproductive and developmental toxicity elements of the study are presented in Section 7.8). Males were used to evaluate toxicity and reproductive parameters. Males and toxicity group females were treated for 29 and 28 days, respectively. Animals were observed throughout the exposure period for mortality and signs of toxicity, FOB and motor activity evaluations were conducted on males and toxicity phase females. Body weights and food consumption were monitored. Haematology and clinical chemistry investigations were conducted on blood samples taken at termination. Complete necropsies were performed on males and toxicity phase females, and selected organs were weighed. Microscopic examinations were performed on selected tissues from the control and high dose toxicity subgroup animals. There were no deaths or adverse findings in the FOB and motor activity tests. Clinical signs were limited to uncoordinated gait and decreased activity immediately after exposure in the highest exposure group. There was a statistically significant decrease in absolute body weights for females (-15%) with a corresponding decrease in total weight gain compared to controls for both sexes (62 and 25% for females and males, respectively) in the highest dose group. Absolute body weights for the mid dose group females were identified as statistically decreased (-7%) from controls, however, total and percent weight gain were not different. Total food consumption was statistically decreased for the highest dose group males and females. Increased red blood cell counts, hemoglobin, and haematocrit were noted in the highest dose group females. Decreased glucose along with increased cholesterol levels, were noted in the highest dose group females with cholesterol and sodium levels statistically increased in the highest dose group males. Organ weight changes included statistically significant decreases in absolute epididymides weight in the high dose males and lung weights in the high dose group females, with increases in kidney-to-body weight ratios for mid and high dose group females and high dose group males. Increased liver-to-body weight ratios were also noted in the high dose group females. There were no gross findings. Histopathological examination of tissues and organs for control and high exposure animals demonstrated an increased incidence of centrilobular hypertrophy in the liver of high dose group females. Evaluation of intermediate dose levels confirmed this finding was limited to high dose group females. There were no other test article-related histopathological findings. The NOAEC for repeated dose toxicity endpoints for 1,1,1,3,3,3-hexamethyldisilazane, based on the clinical observation, body weight changes and histological findings was 100 ppm (660 mg/m3). There were no test article-related effects observed on reproductive and developmental parameters (Dow Corning Corporation, 2008).
There is another inhalation study conducted according to OECD Test Guideline 422 and in compliance with GLP on the hydrolysis product, trimethylsilanol (CAS 1066-40-6) in which three groups of Sprague-Dawley rats were exposed, via whole-body inhalation to vapor atmospheres of the test article for 6 hours/day, 7 days/week for 4 weeks, at 0, 60, 300 and 600 ppm.
Test substance-related effects were limited to changes in haematology (lower eosinophil and lymphocyte counts for males) and serum chemistry (higher alanine aminotransferase for males and toxicity phase females) at 600 ppm. These changes occurred in the absence of correlating histologic changes and were not considered adverse. Therefore, under the conditions of this screening study, an exposure level of at least 600 ppm (2214 mg/m3) was considered to be the NOAEC (WIL Research Laboratories, 2008).
Repeat dose information (OECD SIDS, 2007) for the non-silanol hydrolysis product, ammonia, indicates that in studies conducted by the inhaled route, the main effects are irritation and inflammation of the respiratory tract. Growth retardation and effects on the CNS were also noted in inhaled studies in rats conducted with ammonium sulfate. Although effects on the respiratory tract were not noted in the repeat dose inhalation study with 1,1,1,3,3,3-hexamethydisilazane, the clinical signs and body weight effects may be attributable to its rapid hydrolysis and production of ammonia and/or trimethylsilanol.
In a brief summary of a non-standard inhalation toxicity study (reliability score 4) the lowest Toxic Concentration for 1,1,1,3,3,3-hexamethyldisilazane was 98 mg/m3 in rats following 17 weeks of intermittent exposure.
There were no repeat dose data for 1,1,1,3,3,3-hexamethyldisilazane via the oral and dermal routes.
Justification for classification or non-classification
Based on the available data, 1,1,1,3,3,3-hexamethyldisilazane does not require classification for specific target organ toxicity according to Regulation (EC) 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.